Most of these agents have been approved in different settings for the treatment of patients with NSCLC (3–8), which has led the scientific community to advance by exploring combinations of anti-PD-(L)1 blockade agents with chemotherapy and/or other immune-checkpoint blockade to achieve better results (9–11). Here, CD274 is linked to non-small cell lung carcinoma.